The settlement benefits consumers who purchased Theranos testing services between November 2013 and June 2016, regardless of whether they paid for these services out of pocket, through health insurance or through any other source. The settlement also benefits two statewide subclasses: an Arizona subclass of class members who made Theranos purchases in Arizona between November 2013 and June 2016 and a California subclass of class members who made Theranos purchases in California between September 2013 and June 2016. The settlement also benefits a Walgreens Edison subclass of Theranos purchasers who were subjected to “tiny” blood draws or fingerpricks by a Walgreens employee between November 2013 and March 2015.
